OSE Immunotherapeutics
Mar 05, 2024
Bayer’s New Cardiology Drug Acoramidis; Two Datopotamab Deruxtecan Applications Validated in the EU; AbbVie and OSE Immunotherapeutics Announce Announces Partnership; vTv Therapeutics Makes Major Move With Cadisegliatin; A2 Bio Scores FDA Orphan Drug Designation for its Therapy, A2B530; FDA Fast Track Designation for AlloNK® in Lupus Nephritis
Acoramidis Joins Bayer's Robust Lineup, Boosting Cardiology Solutions Bayer has obtained the exclusive rights to market acoramidis in Europe from Eidos Therapeutics Inc., BridgeBio International GmbH, and BridgeBio Europe B.V. Acoramidis, a highly potent and selective small molecule given orally, functions as a ...
Read More...
Apr 24, 2020
Changing the Paradigm of Cancer: Neoantigen based Personalized Cancer Therapeutic Vaccines
Neoantigen based Personalized Cancer Therapeutic Vaccines Market is advancing owing to bioinformatics-technological advancements, improved diagnosis, and a strong pipeline. Cancer therapeutic vaccines, unlike prophylactic vaccines, form a therapeutic option for the late-stage cancer patients in which the body’...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
